ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J01DD04 | G | Ceftriaxone (sodium) - 0.5g | 11722 | 100323/1 | LEBACEF | 0.5g | 10 | Injectable powder for solution | IV/IM | Raymond Georges Abou Adal & Co | ACS Dobfar SpA, Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 3,858,748 L.L | 23.08 | B | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
J01DD04 | G | Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - | 6786 | 97386/12 | LEBACEF | 0.5g | 1 | Injectable powder for solution+diluent | IM | Raymond Georges Abou Adal & Co | Mitim SRL Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 511,940 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (sodium) - 0.5g | 6787 | 97389/12 | LEBACEF | 0.5g | 1 | Injectable powder for solution+diluent | IV | Raymond Georges Abou Adal & Co | Mitim SRL Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 511,940 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (sodium) - 0.5g | 6891 | 97494/12 | LEBACEF | 0.5g | 10 | Injectable powder for solution | IV/IM | Raymond Georges Abou Adal & Co | Mitim SRL Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 3,455,595 L.L | 23.08 | B | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (sodium) - 0.5g | 7618 | 45714/1 | LEBACEF | 0.5g | 1 | Injectable powder for solution+diluent | IV | Raymond Georges Abou Adal & Co | Mitim SRL Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 433,869 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - | 11034 | 104022/1 | LEBACEF | 0.5g | 1 | Injectable powder for solution+diluent | IM | Raymond Georges Abou Adal & Co | Mitim SRL Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 403,153 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (sodium) - 0.5g, Lidocaine (ampoule) - | 11721 | 142023/1 | LEBACEF | 0.5g | 1 | Injectable powder for solution+diluent | IM | Raymond Georges Abou Adal & Co | ACS Dobfar SpA, Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 403,153 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (sodium) - 0.5g | 11723 | 81923/1 | LEBACEF | 0.5g | 1 | Injectable powder for solution+diluent | IM | Raymond Georges Abou Adal & Co | ACS Dobfar SpA, Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 622,007 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (sodium) - 0.5g | 11724 | 81823/1 | LEBACEF | 0.5g | 1 | Injectable powder for solution+diluent | IV | Raymond Georges Abou Adal & Co | ACS Dobfar SpA, Italy for Arwan Pharmaceutical Industries Lebanon SAL | Lebanon | 643,765 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (disodium) (Vial) - 500mg, Lidocaine (ampoule) - | 5202 | 194125/05 | MEDAXONUM | 500mg | 1 | Injectable powder for solution+diluent | IM | New Allpharma | Medochemie Ltd | Cyprus | 307,740 L.L | 23.08 | A1 | Medochemie Ltd | Cyprus | 2/5/2024 | 0 |
J01DD04 | G | Ceftriaxone - 0.5g/2ml, Lidocaine (ampoule) - | 7819 | 69614/1 | MEGION-A | 0.5g/2ml | 1 x 2ml | Injectable powder + solvent | IM | Khalil Fattal & Fils S.A.L. | Pharmaline under license from Sandoz GmbH, Austria | Lebanon | 332,252 L.L | 23.08 | A1 | 2/5/2024 | 0 | ||
J01DD04 | G | Ceftriaxone (sodium) - 500mg | 1618 | 405685/00 | TRIAXONE | 500mg | 1 x 2ml | Injectable powder for solution+diluent | IM | Pharmanet Drugstore S.A.R.L. | Julphar | United Arab Emirates | 356,118 L.L | 23.08 | A1 | 2/5/2024 | 0 |